Hospital
CMSC, LLC
CMSC, LLC was paid $2.60M by Medicaid between Jan 2018 and Dec 2024, across 258 billing codes. Its largest line is 99283, emergency room visit (moderate) — 32% of everything it billed.
33Billing provider infoCMSC, LLC
GREAT FALLS, MT 59405
GREAT FALLS, MT 59405
33aNPI1639109978assigned 07/03/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$2.60M
24GClaims468,292
24DCodes billed258
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Montana
Rank by total paid#2 of 10
Median peer was paid$774K
This provider vs. median3.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official BALDOCK, JENNIFER controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 66,127 | $310K | |
| 2019 | 55,829 | $261K | |
| 2020 | 55,059 | $194K | |
| 2021 | 69,826 | $322K | |
| 2022 | 76,429 | $558K | |
| 2023 | 87,208 | $559K | |
| 2024incomplete | 57,814 | $393K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 32% | 23,068 | 20,253 | $836K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 27% | 12,692 | 10,970 | $690K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 4.3% | 6,135 | 2,575 | $112K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.1% | 5,578 | 4,991 | $81K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.0% | 2,169 | 1,706 | $77K |
| 87631 | 2.1% | 2,443 | 2,232 | $55K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.8% | 2,998 | 2,693 | $45K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 1,476 | 1,244 | $35K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.0% | 29,796 | 23,473 | $26K |
| 87430 | <1% | 5,124 | 4,590 | $26K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,240 | 4,154 | $25K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 536 | 368 | $25K |
246 more codes
| 86003 | <1% | 463 | $22K | |
| 99285 | Emergency room visit (most serious) | <1% | 1,580 | $21K |
| 73110 | <1% | 1,462 | $21K | |
| 80050 | General health panel | <1% | 3,967 | $20K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,982 | $18K |
| 80053 | Comprehensive metabolic panel | <1% | 21,531 | $18K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 5,651 | $16K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 875 | $16K |
| 73562 | <1% | 2,303 | $15K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,812 | $15K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,787 | $15K |
| 73630 | <1% | 2,001 | $14K | |
| 73610 | <1% | 1,513 | $14K | |
| J3490 | Unclassified drugs | <1% | 11,066 | $13K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 35 | $13K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,454 | $13K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,957 | $13K |
| 36415 | Collection of venous blood by venipuncture | <1% | 48,523 | $12K |
| G0378 | Hospital observation service, per hour | <1% | 1,758 | $11K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 413 | $10K |
| 80061 | Lipid panel | <1% | 6,056 | $10K |
| 87070 | <1% | 4,041 | $10K | |
| 73130 | <1% | 1,215 | $10K | |
| 87641 | <1% | 4,777 | $9K | |
| 92523 | <1% | 150 | $8K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,220 | $8K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 1,056 | $8K |
| 74018 | <1% | 945 | $7K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,818 | $7K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,890 | $7K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,770 | $6K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,770 | $6K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,162 | $6K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,993 | $6K |
| 81001 | <1% | 9,277 | $6K | |
| 84439 | <1% | 2,721 | $6K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 286 | $6K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 13 | $5K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 386 | $5K |
| 87081 | <1% | 2,721 | $5K | |
| 70486 | <1% | 55 | $5K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,451 | $4K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 858 | $4K |
| 73030 | <1% | 1,138 | $4K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,919 | $4K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 41 | $3K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 67 | $3K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,780 | $3K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 48 | $3K |
| 81025 | <1% | 2,436 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,058 | $3K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 29 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,361 | $2K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 374 | $2K |
| 97161 | <1% | 726 | $2K | |
| 82728 | <1% | 1,191 | $2K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 85 | $2K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,122 | $2K |
| 72100 | <1% | 592 | $2K | |
| 83690 | <1% | 3,951 | $2K | |
| 81003 | <1% | 5,525 | $2K | |
| 84702 | <1% | 2,475 | $2K | |
| 87186 | <1% | 1,825 | $2K | |
| 86140 | <1% | 3,381 | $2K | |
| 85651 | <1% | 3,414 | $2K | |
| 62323 | <1% | 76 | $2K | |
| 81015 | <1% | 1,989 | $1K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,266 | $1K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 456 | $1K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,150 | $1K |
| 83735 | <1% | 3,108 | $1K | |
| 87077 | <1% | 921 | $1K | |
| 86803 | <1% | 2,145 | $1K | |
| 83540 | <1% | 1,311 | $1K | |
| 83550 | <1% | 1,267 | $1K | |
| J2704 | Injection, propofol, 10 mg | <1% | 6,153 | $1K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 107 | $988.55 |
| 87400 | <1% | 111 | $872.10 | |
| 80055 | <1% | 465 | $800.02 | |
| 87071 | <1% | 392 | $789.28 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 101 | $778.47 |
| 82785 | <1% | 177 | $777.75 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 76 | $685.43 |
| 73502 | <1% | 277 | $663.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 6,050 | $653.54 |
| 87205 | <1% | 804 | $634.07 | |
| 83516 | <1% | 28 | $612.00 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 501 | $591.57 |
| 87581 | <1% | 223 | $578.00 | |
| 87486 | <1% | 223 | $574.60 | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 497 | $568.80 |
| 87653 | <1% | 2,051 | $558.45 | |
| 80081 | <1% | 749 | $545.70 | |
| 73140 | <1% | 53 | $536.34 | |
| 89220 | <1% | 70 | $530.40 | |
| 85730 | <1% | 1,669 | $528.86 | |
| 84703 | <1% | 707 | $525.23 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,270 | $513.20 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,177 | $512.44 |
| 84484 | <1% | 2,944 | $509.04 | |
| 86780 | <1% | 844 | $500.34 | |
| 85610 | <1% | 2,714 | $467.32 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 8,026 | $465.92 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 299 | $463.25 |
| 87640 | <1% | 4,111 | $455.88 | |
| 82607 | <1% | 579 | $450.50 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,913 | $419.16 |
| 85379 | <1% | 1,130 | $401.59 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,552 | $384.79 |
| 83880 | <1% | 767 | $368.04 | |
| 87210 | <1% | 1,186 | $356.14 | |
| 12001 | <1% | 14 | $355.40 | |
| 87088 | <1% | 512 | $350.57 | |
| 83655 | <1% | 49 | $344.25 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 159 | $321.50 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 6,261 | $316.42 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 375 | $306.63 |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 182 | $306.59 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,301 | $302.60 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,236 | $295.04 |
| 87147 | <1% | 661 | $294.51 | |
| 87040 | <1% | 33 | $289.16 | |
| 76830 | Ultrasound, transvaginal | <1% | 725 | $279.65 |
| 80074 | <1% | 14 | $269.53 | |
| 73080 | <1% | 18 | $232.05 | |
| 72040 | <1% | 70 | $226.10 | |
| 87220 | <1% | 442 | $216.75 | |
| 73521 | <1% | 13 | $215.90 | |
| 92551 | <1% | 84 | $215.45 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,948 | $210.87 |
| 83970 | <1% | 262 | $204.00 | |
| 80076 | <1% | 126 | $203.15 | |
| L8699 | Prosthetic implant, not otherwise specified | <1% | 40 | $192.54 |
| 80377 | <1% | 211 | $179.00 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,759 | $148.79 |
| 82570 | <1% | 912 | $138.54 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 438 | $132.12 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 540 | $130.41 |
| 86593 | <1% | 701 | $128.78 | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 857 | $126.08 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,522 | $125.22 |
| 80069 | <1% | 1,021 | $124.10 | |
| 82784 | <1% | 14 | $112.20 | |
| 82150 | <1% | 270 | $106.24 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 414 | $95.14 |
| 82948 | <1% | 931 | $89.23 | |
| 82746 | <1% | 16 | $85.85 | |
| 82977 | <1% | 13 | $81.59 | |
| 84156 | <1% | 229 | $75.90 | |
| 82947 | <1% | 67 | $74.80 | |
| 82043 | <1% | 276 | $71.82 | |
| 86255 | <1% | 13 | $65.45 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 109 | $63.63 |
| 86677 | <1% | 32 | $56.10 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 263 | $45.99 |
| 82950 | <1% | 1,086 | $45.90 | |
| 86318 | <1% | 91 | $41.06 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 508 | $40.49 |
| 83615 | <1% | 20 | $37.48 | |
| 86431 | <1% | 37 | $36.63 | |
| 87185 | <1% | 15 | $35.70 | |
| A4217 | Sterile water/saline, 500 ml | <1% | 246 | $34.26 |
| 84550 | <1% | 274 | $23.80 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 782 | $16.93 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 425 | $15.26 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 132 | $8.49 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 89 | $7.33 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 118 | $3.40 |
| 97035 | 0% | 89 | $0.00 | |
| 99156 | 0% | 1,073 | $0.00 | |
| 84153 | 0% | 219 | $0.00 | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 0% | 118 | $0.00 |
| 88304 | 0% | 104 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 115 | $0.00 |
| V2632 | Posterior chamber intraocular lens | 0% | 249 | $0.00 |
| 83605 | 0% | 149 | $0.00 | |
| 76536 | 0% | 12 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 25 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 53 | $0.00 |
| 84134 | 0% | 90 | $0.00 | |
| 96376 | 0% | 35 | $0.00 | |
| 86317 | 0% | 47 | $0.00 | |
| 87340 | 0% | 126 | $0.00 | |
| 82575 | 0% | 43 | $0.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 49 | $0.00 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 0% | 34 | $0.00 |
| 87522 | Neg quan hep c or qual rna | 0% | 28 | $0.00 |
| 86592 | 0% | 123 | $0.00 | |
| 93351 | 0% | 12 | $0.00 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 16 | $0.00 |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 0% | 103 | $0.00 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 71 | $0.00 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 31 | $0.00 |
| 73560 | 0% | 16 | $0.00 | |
| 82550 | 0% | 19 | $0.00 | |
| 82378 | 0% | 15 | $0.00 | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | 0% | 249 | $0.00 |
| 86704 | 0% | 60 | $0.00 | |
| G0379 | Direct admission of patient for hospital observation care | 0% | 24 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 33 | $0.00 |
| 97162 | 0% | 15 | $0.00 | |
| 86706 | 0% | 35 | $0.00 | |
| 74021 | 0% | 64 | $0.00 | |
| J2469 | Injection, palonosetron hcl, 25 mcg | 0% | 30 | $0.00 |
| 80320 | 0% | 13 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 50 | $0.00 |
| 73090 | 0% | 13 | $0.00 | |
| 83520 | 0% | 12 | $0.00 | |
| 93971 | 0% | 25 | $0.00 | |
| 99153 | Mod sedat endo service >5yrs | 0% | 24 | $0.00 |
| 86901 | 0% | 38 | $0.00 | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 0% | 16 | $0.00 |
| C1769 | Guide wire | 0% | 15 | $0.00 |
| 99157 | 0% | 757 | $0.00 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 0% | 1,880 | $0.00 |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 0% | 599 | $0.00 |
| 80305 | 0% | 103 | $0.00 | |
| 86480 | 0% | 45 | $0.00 | |
| 72110 | 0% | 72 | $0.00 | |
| 86703 | 0% | 781 | $0.00 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 0% | 17 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 172 | $0.00 |
| 90715 | 0% | 45 | $0.00 | |
| 77080 | 0% | 25 | $0.00 | |
| 99152 | 0% | 71 | $0.00 | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 0% | 167 | $0.00 |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 0% | 51 | $0.00 |
| 84145 | 0% | 135 | $0.00 | |
| 76000 | 0% | 157 | $0.00 | |
| J3300 | Injection, triamcinolone acetonide, preservative free, 1 mg | 0% | 307 | $0.00 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 115 | $0.00 |
| 0223U | 0% | 181 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 187 | $0.00 |
| 86038 | 0% | 13 | $0.00 | |
| 96367 | 0% | 132 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 40 | $0.00 |
| 86900 | 0% | 37 | $0.00 | |
| J0694 | Injection, cefoxitin sodium, 1 gm | 0% | 51 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 32 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 19 | $0.00 |
| 86708 | 0% | 35 | $0.00 | |
| 71250 | 0% | 18 | $0.00 | |
| 84100 | 0% | 16 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 22 | $0.00 |
| 84403 | 0% | 19 | $0.00 | |
| 93325 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBALDOCK, JENNIFER (OFFICIAL)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.